Cargando…
Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disea...
Autores principales: | Gan, Jing, Wu, Yansheng, Gong, Xuezhong, Ma, Yiyi, Yu, Shengqiang, Gao, Jiandong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686499/ https://www.ncbi.nlm.nih.gov/pubmed/31391092 http://dx.doi.org/10.1186/s13063-019-3563-5 |
Ejemplares similares
-
Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023) -
Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022) -
Kidney volume and function in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2013) -
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022) -
Developments in the management of autosomal dominant polycystic
kidney disease
por: Masoumi, Amirali, et al.
Publicado: (2008)